Recently, Suzhou Xueji Biotechnology Co., Ltd. (hereinafter referred to as "Xueji Biotech") announced the completion of over RMB 100 million in Series B1 equity financing, and secured over RMB 100 million in credit-based debt financing from multiple banks. The proceeds will be allocated to the company’s core business—the ex vivo regeneration of platelet lineage—to address issues such as blood supply shortage and blood-borne diseases, drastically reduce adverse reactions caused by blood transfusion, as well as develop novel drugs derived from regenerated platelets.

The first tranche of this round of Series B1 equity financing, totalling over RMB 100 million, was led by Hainan Grand Health Medical Group, with participation from Yonghui Ventures and other investors. The funds will be mainly used for clinical trials of Xueji Biotech’s first two pipelines and preclinical development of other key pipelines to support the company’s rapid growth. Meanwhile, the second tranche of Series B1 financing is underway and expected to close in the coming months.

In the meantime, Xueji Biotech has obtained RMB 120 million in bank credit lines, which will serve as reserves for the company’s development. The granting banks include China Merchants Bank Suzhou Branch, Bank of Ningbo Co., Ltd. Suzhou Area Branch of Jiangsu Pilot Free Trade Zone, Bank of Shanghai Co., Ltd. Suzhou Branch and China Construction Bank Corporation Suzhou Branch.

Xueji Biotech’s independently developed world’s first-in-class products—two megakaryocyte products—have respectively obtained IND (Investigational New Drug) approvals from the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA). Using hematopoietic stem cells as the source cells, the products generate high-quality, large-scale, stable and controllable megakaryocytes through a directed differentiation system featuring serum-free, feeder-free, non-immortalized and impurity-free processes without any gene editing, targeting the vast global thrombopoietic drug market. In addition, according to the company’s pipeline development progress, around four to five new drug IND applications will enter the approval phase in 2026.

Xueji Biotech has also achieved outstanding results in developing the world’s first-in-class ex vivo induced differentiated platelet injection, with multiple products being the first to receive FDA Orphan Drug Designation (ODD), including hematopoietic stem cell-derived and iPSC-derived platelet injections. Statistics show that Xueji Biotech has obtained 5 ODDs and 2 RPDDs (Rare Pediatric Disease Designation) from the FDA, providing new therapeutic options for rare hematological diseases.

Following this round of financing, Xueji Biotech will launch its overseas expansion layout, aiming to let Chinese original innovation shine globally and bring about the second blood transfusion revolution for the world!

Voices from Enterprises & Capital

Zhu Fangfang, Founder of Xueji Biotech, stated, "We appreciate the investors for their investment in this round. The proceeds will fully support us in sprinting toward the final stages of drug R&D and key milestones of company growth. The scarcity of Xueji Biotech’s products, steady development strategy and sound financial status have given investors ample confidence in this capital increase. Though R&D and pioneering in new fields and novel drugs are fraught with hardships and challenges, our technological breakthroughs and the external industrial ecosystem have endowed us with sufficient strength and courage to pursue our mission of 'Regenerate Vital Blood, Sustain Life with Xueji'."

Tang Jinjun, CFO of Hainan Grand Health Medical Group, commented, "Hainan Grand Health Medical Group Co., Ltd. firmly favors Xueji Biotech’s growth potential and team strength, and we are honored to lead the investment in this round. As a professional institution with profound industrial accumulation and rich investment experience in the big health sector, we will not only inject valuable capital into Xueji Biotech, but also provide strong empowerment in strategic resource integration and industrial synergistic development. Combined with our own layout in the healthcare sector and the partial business overlaps with Xueji Biotech, we firmly believe this investment marks the starting point for complementary resources, strategic synergy and in-depth cooperation between the two sides, ultimately achieving a win-win situation in both commercial and social values in respective fields."

Li Yanhao, Partner of Yonghui Ventures, said, "Yonghui Ventures is honored to participate in Xueji Biotech’s this round of financing, and we are long-term optimistic about the company’s groundbreaking technological barriers in platelet drug R&D, as well as the precise layout and market value of its thrombopoietic drugs. We fully trust the R&D and operational capabilities of the company’s core team, which is expected to achieve major breakthroughs in the hematological drug field. Going forward, we will join hands with the company for mutual growth and inject strong new momentum into the innovative development of China’s biopharmaceutical industry."

About Xueji Biotech

Founded in June 2021 in the Biomedical Industry Park of Suzhou Industrial Park, Xueji Biotech is an overseas-returnee expert-founded novel cell therapy firm dedicated to ex vivo hematopoietic lineage regeneration (blood cells & immune cells). Endowed with unique stem cell reprogramming, editing and differentiation technologies, it takes ex vivo platelet regeneration as its top priority and core focus, and enters the cell therapy sector centered on directed differentiation of adult stem cells and iPSCs.